Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Barclays PLC

Barclays PLC grew its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 113.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 125,397 shares of the company’s stock after purchasing an additional 66,550 shares during the quarter. Barclays PLC owned 0.16% of Viridian Therapeutics worth $2,851,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Quest Partners LLC boosted its stake in Viridian Therapeutics by 344.0% during the second quarter. Quest Partners LLC now owns 6,056 shares of the company’s stock valued at $79,000 after buying an additional 4,692 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Viridian Therapeutics in the 3rd quarter worth approximately $149,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Viridian Therapeutics by 24.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company’s stock worth $156,000 after purchasing an additional 2,359 shares in the last quarter. Arizona State Retirement System lifted its stake in Viridian Therapeutics by 14.7% during the second quarter. Arizona State Retirement System now owns 13,178 shares of the company’s stock valued at $171,000 after purchasing an additional 1,688 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in Viridian Therapeutics during the third quarter worth approximately $208,000.

Insider Transactions at Viridian Therapeutics

In other news, CEO Stephen F. Mahoney purchased 21,400 shares of the company’s stock in a transaction dated Friday, September 27th. The shares were bought at an average price of $23.33 per share, with a total value of $499,262.00. Following the completion of the transaction, the chief executive officer now directly owns 21,400 shares in the company, valued at $499,262. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Thomas W. Beetham acquired 5,000 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The shares were purchased at an average cost of $23.41 per share, with a total value of $117,050.00. Following the completion of the acquisition, the chief operating officer now owns 6,000 shares in the company, valued at $140,460. This trade represents a 500.00 % increase in their position. The disclosure for this purchase can be found here. 0.65% of the stock is currently owned by company insiders.

Viridian Therapeutics Stock Performance

VRDN stock opened at $19.31 on Wednesday. The firm has a 50 day simple moving average of $21.64 and a 200 day simple moving average of $18.25. Viridian Therapeutics, Inc. has a 52 week low of $11.40 and a 52 week high of $27.20. The stock has a market cap of $1.53 billion, a P/E ratio of -4.48 and a beta of 1.04. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55.

Viridian Therapeutics (NASDAQ:VRDN) last issued its earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). The company had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.08 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. Research analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on VRDN shares. HC Wainwright reiterated a “buy” rating and set a $34.00 price objective on shares of Viridian Therapeutics in a research report on Monday, December 16th. Needham & Company LLC reaffirmed a “buy” rating and set a $38.00 target price on shares of Viridian Therapeutics in a research report on Monday, November 25th. The Goldman Sachs Group increased their price target on Viridian Therapeutics from $25.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, September 12th. Wells Fargo & Company restated an “equal weight” rating and set a $27.00 price objective (down previously from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. Finally, Royal Bank of Canada raised their target price on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the stock an “outperform” rating in a report on Tuesday, December 17th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, Viridian Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $35.70.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.